KREX Packages

Product number 30008


CodeProduct Description
30008EKREX™ EVAL Package - IMMUNOME™ V4 Discovery Array Service of 50 samples
30008XKREX™ EXPLORE Package - IMMUNOME™ V4 Discovery Array Service of 100 samples
30008VKREX™ VALIDATE Package - IMMUNOME™ V4 Discovery Array Service of 400 samples


IMMUNOME™ v4 Discovery Array is a protein array which utilises the patented Sengenics KREX™ functional proteomics technology. All proteins on the IMMUNOME™ v4 Discovery Array are correctly folded and functional as they are expressed as fusion proteins with biotin carboxyl carrier protein (BCCP) which acts as a folding marker and solubility enhancer. The IMMUNOME™ v4 Discovery Array contains 1600+ full-length human proteins from biologically significant protein families including kinases, signalling molecules, cytokines, interleukins, chemokines and cancer antigens. The arrays are coated with a proprietary surface which preserves protein folding and inhibits binding of non-specific proteins.

1. Discovery of autoantibody biomarkers for precision immuno-profiling

2. Discovery of autoantibody biomarkers of risk of adverse drug reactions

3. Discovery of autoantibody-based therapeutic and prophylactic biologics

4. Selectivity screens for new chemical entities and new biologics

5. Functional assays for any protein and any interacting biomolecule


Product name:

IMMUNOME™ v4 Discovery Array Packages

Minimum Order : 30 slides

Slide Type: Streptavidin-coated glass slide

Species: Human

Storage: Store for up to 12 months at -20°c

Delivery lead time: 4 weeks


Resources to access our technology


Your technical questions - answered


One technology - endless possibilities

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics UK Ltd. Registered in England and Wales no. 12889389 | Sengenics Corporation Pte. Ltd. Registered in Singapore no. 201734100D